OvaScience Inc  

(Public, NASDAQ:OVAS)   Watch this stock  
Find more results for OVAS
1.48
+0.03 (2.07%)
Feb 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.42 - 1.51
52 week 1.30 - 11.66
Open 1.45
Vol / Avg. 710,073.00/808,706.00
Mkt cap 53.79M
P/E     -
Div/yield     -
EPS -2.71
Shares 35.61M
Beta 3.99
Inst. own 65%
Feb 23, 2017
Q4 2016 OvaScience Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -9792.39% -26432.85%
Operating margin -9626.40% -25992.42%
EBITD margin - -25528.16%
Return on average assets -51.39% -71.72%
Return on average equity -55.98% -80.38%
Employees 87 -
CDP Score - -

Address

9 4th Ave
WALTHAM, MA 02451-7506
United States - Map
+1-617-5002802 (Phone)
+1-302-6554620 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company's portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient's own ovarian tissue. The Company's AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient's own EggPC cells are added to the patient's mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman's ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman's own EggPC cells without the need for hormone hyperstimulation.

Officers and directors

Michelle Dipp M.D., Ph.D. Executive Chairman of the Board, Acting President, Chief Executive Officer, Principal Executive Officer
Age: 39
Bio & Compensation  - Reuters
Christophe Couturier Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Karen Long Executive Vice President - Clinical and Regulatory Affairs and Quality Assurance
Bio & Compensation  - Reuters
James Luterman Ph.D. Executive Vice President - Research and Development
Bio & Compensation  - Reuters
Theresa McNeely Executive Vice President, Chief Communications Officer
Age: 51
Bio & Compensation  - Reuters
Ravi Mehrotra Ph.D. Chief Corporate Development Officer
Bio & Compensation  - Reuters
John P. Howe III M.D. Director
Age: 66
Bio & Compensation  - Reuters
John E. Sexton Ph.D. Director
Bio & Compensation  - Reuters
Jeffrey D. Capello Independent Director
Age: 50
Bio & Compensation  - Reuters
Mary M. Fisher Independent Director
Age: 54
Bio & Compensation  - Reuters